Rapport Therapeutics (RAPP) CDO Krishnaswamy Sells Shares

What Happened

• Yeleswaram Krishnaswamy, Chief Development Officer of Rapport Therapeutics (RAPP), sold a total of 50,160 shares in open‑market transactions on August 24–25, 2026, generating roughly $2.53 million in proceeds. The sales were executed under a preplanned Rule 10b5‑1 trading plan adopted December 10, 2025.
• Breakdown: 13,160 shares on 2026‑08‑24 at a weighted average price of $50.00 for ~$657,978; 20,799 shares on 2026‑08‑25 at a weighted average price of $50.31 for ~$1,046,421; and 16,201 shares on 2026‑08‑25 at a weighted average price of $51.06 for ~$827,184. The filing shows the shares were disposed (sales).

Key Details

• Transaction dates: Aug 24, 2026 (13,160 shares) and Aug 25, 2026 (20,799 and 16,201 shares).
• Reported weighted average prices and ranges:
  • 13,160 shares — $50.00 (weighted avg); individual prices ranged $49.90–$50.25 (footnote F2).
  • 20,799 shares — $50.31 (weighted avg); individual prices ranged $49.90–$50.88 (footnote F3).
  • 16,201 shares — $51.06 (weighted avg); individual prices ranged $50.91–$51.39 (footnote F4).
• Total proceeds: about $2.53 million.
• Shares owned after the transactions: not specified in the provided filing excerpt.
• Footnote: sales were made pursuant to a Rule 10b5‑1 trading plan adopted Dec 10, 2025 (footnote F1). The weighted‑average prices reflect multiple executions; the filer offers to provide detailed per‑price breakdowns on request.
• Timeliness: Form 4 was filed Aug 26, 2026 for transactions on Aug 24–25; this appears to be filed within the standard two‑business‑day window for insiders.

Context

• These were sales (dispositions), not purchases or option exercises. Sales executed under a 10b5‑1 plan are preplanned and often undertaken for diversification or liquidity needs; they do not necessarily signal a change in insider sentiment about the company.
• For retail investors, purchases by insiders often carry more interpretive weight than planned sales. This filing documents realized proceeds and confirms the sales were prearranged and timely reported.